Seattle Genetics inks drug licensing deal worth up to $1.2 billion
February 12, 2018 at 13:05 PM EST
The deal to develop next-generation treatments follows Seattle Genetics' $614 million acquisition of Cascadian Therapeutics last week.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.